King & Wood Mallesons has advised Ysios Capital on the closing of a €216 million fund, Ysios BioFund III
This is Ysios Capital´s third fund, Ysios BioFund III, which has reached a final size of €216 million. The fund will invest broadly across multiple therapeutic areas and modalities, targeting seed/early stage and development-stage companies at the forefront of the future of medicine. The total investment size per company will typically be up to €20 million.
Ysios Biofund III has been supported by the European Investment Fund with nearly €60 million. Other investors are insurance companies, family offices, pension funds, local agencies, business corporations, as well as the main partners of the private equity firm.
Joël Jean-Mairet, Partner of Ysios Capital said: “We are very pleased with our achievements in the last twelve years and we are particularly proud of our investments supporting great entrepreneurs in Spain.”
Ysios Capital is the largest venture capital firm in Spain specialized in biotechnology, with € 346M under management, through three funds; Ysios BioFund I (€ 65M), Ysios BioFund II Innvierte (€ 126M) and Ysios BioFund III (€ 155M), open to new investors.
The team has been strengthened with five Venture Partners to support the evaluation of potential investments. Ysios BioFund III has a solid investor base with a high repetition rate. Investors from previous funds who are participating increased their previous commitments by 60% on average.
Isabel Rodríguez (pictured left), partner and head of the Funds team at KWM – Spain, was in charge of the coordination of the advice to Ysios Capital. Other key members of the team were partner Ildefonso Alier (pictured top right) and associate María Mata (pictured bottom right). KWM had previously advised Ysios on the structuring of its funds Ysios BioFund I and Ysios BioFund II.